<DOC>
	<DOCNO>NCT00460317</DOCNO>
	<brief_summary>To determine treatment AMG 706 ( motesanib diphosphate ) combination paclitaxel carboplatin improve overall survival compare treatment placebo combination paclitaxel carboplatin subject advance non-squamous NSCLC subject adenocarcinoma histology ( adenocarcinoma subpopulation ) .</brief_summary>
	<brief_title>MONET1-MOtesanib NSCLC Efficacy Tolerability Study</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Histologically confirm , unresectable stage 111B pericardial pleural effusion stage IV recurrent non squamous NSCLC . Measurable nonmeasurable disease per modify RECIST criterion ECOG performance status 0 1 Life expectancy great equal 3 month document investigator ability take oral medication competency give write informed consent able start protocol direct therapy within 7 day date randomization Hematological function , follow : Absolute neutrophil count ( ANC ) &gt; = 1.5 x 109/L Platelet count &gt; = 100 x 109/L &lt; = 850 x 109/L Hemoglobin &gt; =9 g/dL Renal function , follow : Creatinine clearance &gt; 40 mL/min ( calculate Cockcroft Gault formula ) Urinary protein quantitative value &lt; = 30 mg urinalysis &lt; = 1+ dipstick unless quantitative protein &lt; 500 mg 24 hour urine sample Hepatic function , follow : Aspartate aminotransferase ( AST ) &lt; =2.5 x upper limit normal ( ULN ) OR AST &lt; 5 x ULN liver metastases present Alanine aminotransferase ( ALT ) &lt; =2.5 x ULN OR ALT &lt; 5 x ULN liver metastases present Alkaline phosphatase &lt; = 2.0 x ULN OR alkaline phosphatase &lt; 5 x ULN liver bone metastasis present Total bilirubin &lt; 1.5 x ULN OR total bilirubin &lt; 3 X ULN subject UGT1A1 promoter polymorphism ( ie , Gilbert syndrome ) confirm genotyping Invader UGT1A1 Molecular Assay prior randomization Partial thromboplastin ( PTT ) activate partial thromboplastin time ( aPTT ) &lt; = 1 x ULN international normalize ratio ( INR ) &lt; = 1.5 x ULN Subjects adenosquamous histology unclear histology subtype ( eg , otherwise specify ) contain great 10 % squamous cell untreated symptomatic central nervous system metastasis . Subjects history brain metastasis eligible definitive therapy administer ( surgery and/or radiation therapy ) , plan treatment brain metastasis , subject clinically stable corticosteroid least 2 week prior randomization . Prior chemotherapy follow : Any prior chemotherapy advance non squamous NSCLC Any prior adjuvant chemotherapy non squamous NSCLC within 52 week prior randomization . Adjuvant chemotherapy complete &gt; 52 week prior randomization permit . Any prior chemoradiation locally advanced stage III disease . Prior ( within 30 day randomization ) yellow fever vaccination . Central ( chest ) radiation therapy within 28 day prior randomization , radiation therapy within 14 day prior randomization peripheral lesion . History pulmonary hemorrhage gross hemoptysis ( approximately 3 mL bright red blood ) within 6 month prior randomization . Prior targeted therapy , include limited : AMG 706 , inhibitor VEGF ( eg , SU5416 , SU6668 , ZD6474 , SU11248 , PTK787 , AZD2171 , AEE 788 , sorafenib , bevacizumab ) , EGFr ( eg , panitumumab , cetuximab , gefitinib , erlotinib ) . Known history allergy hypersensitivity reaction paclitaxel carboplatin . Any anticoagulation therapy within 7 day prior randomization . The use lowdose warfarin [ &lt; = 2 mg daily ] low molecular weight heparin heparin flush prophylaxis central venous catheter thrombosis allow . History arterial venous thrombosis within 12 month prior randomization . History bleed diathesis bleeding within 14 day prior randomization . Peripheral neuropathy &gt; grade 1 per Common Terminology Criteria Adverse Events ( CTCAE ) Version 3.0 . Clinically significant cardiac disease within 12 month randomization , include myocardial infarction , unstable angina , grade 2 great peripheral vascular disease , cerebrovascular accident , transient ischemic attack , percutaneous transluminal coronary angioplasty/stent , congestive heart failure , ongoing arrhythmias require medication . History primary cancer unless : Curatively resect non melanomatous skin cancer . Curatively treated cervical carcinoma situ . Other primary solid tumor curatively treat know active disease present curative treatment administer last 3 year Any kind disorder compromise ability subject comply study procedure . Open wound , ulcer fracture . Uncontrolled hypertension define rest blood pressure &gt; 150/90 mm Hg . Antihypertensive medication allow subject stable current dose time randomization . Surgery : Major surgical procedure within 28 day prior randomization Minor surgical procedure within 14 day prior randomization Failure recover prior surgery Placement central venous access device ( include port tunnel nontunneled catheter ) within 7 day prior randomization Planned elective surgery study treatment Core needle biopsy within 7 day prior randomization Not recover previous therapy ( ie , radiation , surgery medication ) . Adverse event relate previous therapy must CTCAE grade &lt; = 1 screening return subject 's baseline prior recent previous therapy . Participation therapeutic clinical trial currently receive investigational treatment ( ) within 30 day prior randomization . Pregnant ( eg , positive HCG testserum urine ) breast feed woman . Any subject consenting use adequate contraceptive precaution ( eg , hormonal , barrier abstinence ) course study 6 month last treatment . Known human immunodeficiency virus ( HIV ) , hepatitis B surface antigen hepatitis C positive . Known chronic hepatitis . Active infection require systemic treatment uncontrolled infection &lt; = 14 day prior randomization . History medical psychiatric condition laboratory abnormality opinion investigator may increase risk associate study participation investigational product ( ) administration may interfere interpretation result . Previously randomize study . Not available followup assessment unable comply study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>lung</keyword>
	<keyword>cancer</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>paclitaxel</keyword>
	<keyword>carboplatin</keyword>
	<keyword>placebo</keyword>
	<keyword>angiogenesis</keyword>
	<keyword>VEGF</keyword>
	<keyword>multi kinase inhibitor</keyword>
</DOC>